Evidence map›Paper›PMID 39109287›Full record

ArticleFrontiers in oncology2024

Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma.

Mi Meng, Bo Yu, Jie Luo, Yuju Bai, Lin Li, Shicheng Chen, Sisi He, Hu Ma

Erratum issuedAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Mi Meng *Department of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Bo Yu *Department of Urology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Jie LuoDepartment of Radiation Oncology, Guiqian International General Hospital, Guiyang, China.
Yuju BaiDepartment of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Lin LiDepartment of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Shicheng ChenDepartment of Urology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Sisi HeDepartment of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Hu MaDepartment of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thymic carcinoma (TC) is an uncommon type of thymic epithelial tumors. Patients with relapsed or refractory TCs have a poor prognosis. Immune checkpoint inhibitor monotherapy can be applied as a second-line treatment for such cases. This study reported a TC patient who did not respond to conventional chemotherapy and radiotherapy but achieved prolonged partial remission lasting 17 months following the third-line treatment with anti-programmed cell death-1 inhibitor sintilimab. This patient did not experience any serious side effects associated with sintilimab treatment. The above results demonstrated that sintilimab could be a feasible therapeutic option for refractory TC patients.

Indexed as

anti-PD-1case reportsintilimabtherapeutic optionthymic carcinoma(TC)

Identifiers

PMID39109287
PMCPMC11300210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.